Literature DB >> 23263824

Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance.

Qiang Fu1, Judd W Moul, Lionel Bañez, Leon Sun, Vladimir Mouraviev, Donghua Xie, Thomas J Polascik.   

Abstract

To assess preoperative parameters that may be predictive of pathologic stage T2a (pT2a) and pathologic Gleason score (pGS) ≤ 6 disease in low-risk prostate cancer patients considering active surveillance. A cohort of 1,495 men with low-risk prostate cancer between 1993 and 2009 was utilized. Preoperative assessment focused on patient age, race, diagnostic PSA level, clinical stage, diagnostic biopsy Gleason score, and prostate cancer laterality. Kaplan-Meier curves and a Cox regression model were used for analysis of PSA recurrence. Preoperative parameters were analyzed by univariate and multivariate logistic regression methods. Of 1,495 patients, 187 (12.5 %) were identified with pT2a and pGS ≤ 6 disease. Of the 187 men with pT2a and pGS ≤ 6 disease, only 6 (3.2 %) cases had PSA recurrence. Kaplan-Meier PSA recurrence-free survival curves identified a difference between prostate cancers with pT2a and pGS ≤ 6 and prostate cancers with >pT2a or pGS ≥ 7 disease (p = 0.002). Only biopsy tumor unilaterality (OR, 10.452; p ≤ 0.001) and low diagnostic PSA levels (OR, 0.887; p = 0.003) were independent predictors of prostate cancers with pT2a and pGS ≤ 6 disease on univariate and multivariate logistic regression. Biopsy tumor unilaterality and low diagnostic PSA levels are the independent predictors of pT2a and pGS ≤ 6 disease in low-risk prostate cancer patients. Unilateral cancer by prostate biopsy and low diagnostic PSA level may be the reference to improving the selection of appropriate candidates for active surveillance within a low-risk prostate cancer cohort.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23263824     DOI: 10.1007/s12032-012-0326-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

1.  Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?

Authors:  Peter R Carroll
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

2.  Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

Authors:  Donatello Telesca; Ruth Etzioni; Roman Gulati
Journal:  Biometrics       Date:  2007-05-14       Impact factor: 2.571

Review 3.  Active surveillance for prostate cancer: trials and tribulations.

Authors:  Laurence Klotz
Journal:  World J Urol       Date:  2008-09-24       Impact factor: 4.226

4.  Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.

Authors:  Pär Stattin; Erik Holmberg; Jan-Erik Johansson; Lars Holmberg; Jan Adolfsson; Jonas Hugosson
Journal:  J Natl Cancer Inst       Date:  2010-06-18       Impact factor: 13.506

5.  Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci.

Authors:  John W Davis; Jeri Kim; John F Ward; Xuemai Wang; Hiro Nakanishi; R Joseph Babaian; Patricia Troncoso
Journal:  BJU Int       Date:  2009-11-03       Impact factor: 5.588

6.  Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management.

Authors:  Gary Onik; Matthew Miessau; David G Bostwick
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

7.  Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.

Authors:  Matthew Frank O'Brien; Angel M Cronin; Paul A Fearn; Brandon Smith; Jason Stasi; Bertrand Guillonneau; Peter T Scardino; James A Eastham; Andrew J Vickers; Hans Lilja
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

8.  Contemporary trends in low risk prostate cancer: risk assessment and treatment.

Authors:  Matthew R Cooperberg; Jeannette M Broering; Philip W Kantoff; Peter R Carroll
Journal:  J Urol       Date:  2007-07-20       Impact factor: 7.450

9.  Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?

Authors:  Alexandre E Pelzer; Daniela Colleselli; Jasmin Bektic; Eberhard Steiner; Reinhold Ramoner; Michael Mitterberger; Christian Schwentner; Georg Schaefer; Stefano Ongarello; Georg Bartsch; Wolfgang Horninger
Journal:  BJU Int       Date:  2008-02-05       Impact factor: 5.588

Review 10.  Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?

Authors:  Laurence Klotz
Journal:  Semin Radiat Oncol       Date:  2008-01       Impact factor: 5.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.